Journey Medical's Emrosi Coverage Expands to 65% of US Commercial Lives

Journey Medical Corporation, a commercial-stage pharmaceutical company, has reported that its Emrosi coverage has increased to 65% of U.S. commercial lives. The company is focused on dermatological conditions and markets seven branded and two authorized generic prescription drugs. Its marketed products include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Journey Medical sells two authorized generic products, including sulconazole nitrate cream and solution, and doxycycline hyclate immediate release 50mg tablets.

Journey Medical Corporation (NASDAQ: DERM) has announced a significant milestone in the commercialization of its rosacea treatment, Emrosi™. The company reported that 65% of commercial lives in the United States now have pharmacy benefit coverage for Emrosi™, up from 29% in May 2025 [1]. This rapid expansion in payer coverage is attributed to Journey Medical's targeted contracting strategy, increasing prescription demand, and strong clinical data demonstrating Emrosi's superior efficacy over existing treatments.

The increased coverage represents a substantial commercial milestone for Journey Medical, dramatically improving access and revenue potential for Emrosi™. The expansion in covered lives will directly impact three critical commercial metrics:

1. Accelerated Prescription Growth: By removing reimbursement barriers, the increased coverage is expected to drive prescription growth.
2. Improved Prescription Fulfillment Rates: Fewer patients are likely to abandon prescriptions due to coverage issues, leading to better adherence.
3. Enhanced Gross-to-Net Margins: The reduction in the need for patient assistance programs should improve gross-to-net margins.

Journey Medical's announcement underscores the company's strategic focus on dermatological conditions. The company markets seven branded and two authorized generic prescription drugs, including Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. The specialty pharmacy distribution model suggests a controlled distribution strategy that may provide better pricing control and patient support.

Rosacea affects approximately 16 million Americans and limited effective treatments are available. Emrosi™ is positioned to become the standard of care for rosacea treatment, given its strong clinical differentiation and rapid payer adoption. With expanded coverage, Journey Medical is well-positioned to establish Emrosi™ as a significant revenue driver if prescriber adoption continues.

References:
[1] https://www.stocktitan.net/news/DERM/journey-medical-corporation-announces-expanded-payer-coverage-for-3bvskhfe1esq.html